# Sun Yat-sen University Cancer Center

Source: https://onco.cc/institutions/sysucc/  
OnCo record `sysucc` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sun Yat-sen University Cancer Center is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma and a top enroller for Chinese ADC and PD-1 trials.

## Summary

Sun Yat-sen University Cancer Center in Guangzhou is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma, and a top enroller for Chinese antibody-drug conjugate and PD-1 trials; it ranks sixtieth in the Newsweek/Statista oncology list. Jun Ma's group set the treatment standards for nasopharyngeal carcinoma, the centre ran the JUPITER-02 toripalimab trial and camrelizumab studies, and it leads trials of izalontamab brengitecan, with Mu-Sheng Zeng, Feng Wang and Rui-Hua Xu also listed. OnCo links it to head and neck, gastric, oesophageal and liver cancers, to plasma EBV DNA, to the idea of blood EBV DNA screening across southern China and Southeast Asia, and to the CSCO guidelines. Whether Chinese trial results are accepted by regulators elsewhere is the open question its work keeps testing. Its nasopharyngeal and ADC programmes are the ones to read.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: Guangzhou, CN
- Type: cancer-center
- Website: https://www.sysucc.org.cn

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Sun_Yat-sen_University_Cancer_Center
- Official website: https://www.sysucc.org.cn

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Izalontamab brengitecan](https://onco.cc/drugs/izalontamab-brengitecan/)
- people: [Feng Wang](https://onco.cc/people/wang-feng-sysucc/), [Jun Ma](https://onco.cc/people/ma-jun/), [Li Zhang](https://onco.cc/people/zhang-li-sysucc/), [Mu-Sheng Zeng](https://onco.cc/people/zeng-mu-sheng/), [Rui-Hua Xu](https://onco.cc/people/xu-rui-hua/), [Wenfeng Fang](https://onco.cc/people/fang-wenfeng/)
- trials: [CAPTAIN-1st](https://onco.cc/trials/captain-1st/), [CONTINUUM](https://onco.cc/trials/continuum/), [JUPITER-02](https://onco.cc/trials/jupiter-02/)
- bottlenecks: [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- ideas: [Blood EBV DNA screening for nasopharyngeal cancer across southern China and Southeast Asia](https://onco.cc/ideas/idea-prev-ebv-dna-npc-screening-scaleup/), [Burden-matched funding for trials led in low- and middle-income countries](https://onco.cc/ideas/idea-fund-lmic-burden-match/)
- terms: [Plasma EBV DNA](https://onco.cc/terms/plasma-ebv-dna/)
- collections: [CSCO guidelines (China)](https://onco.cc/collections/csco-guidelines/)
- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [First Affiliated Hospital of Sun Yat-sen University](https://onco.cc/institutions/sysu-first-affiliated-hospital/), [Jinshazhou Hospital of Guangzhou University of Chinese Medicine](https://onco.cc/institutions/jinshazhou-hospital/), [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/)

---
JSON: https://onco.cc/api/v1/entities/sysucc.json